Nuvation Bio (US:NUVB) Seeking Alphaยท2025-11-07 22:23Core Insights - The article presents a bullish case for Nuvation Bio (NUVB) following the commercial launch of its first approved therapy, Ibtrozi [1] Company Analysis - Nuvation Bio is focused on oncology and has recently launched its first therapy, indicating a significant milestone for the company [1] - The author emphasizes the importance of identifying reasonably priced companies with steady long-term growth prospects, which aligns with Nuvation Bio's potential in the biotech sector [1] Investment Strategy - The article highlights the strategy of uncovering small- and mid-cap companies with potential for exponential growth through careful fundamental analysis [1] - The author believes that educated individuals can outperform the market by understanding basic accounting and financial principles, which is relevant for investors considering Nuvation Bio [1]